Teva Pharmaceutical Industries has ridden a powerful re-rating over the past few years, helped by a shift toward branded drugs and a deeper biosimilars push, which naturally raises a basic question for you as an investor. Is the current share price grounded in the cash the business is expected to generate, or has sentiment moved ahead of the underlying economics?
- Over the past 3 years the stock has returned about 398.8%, which puts a lot of weight on whether Teva's future cash flows can support such a sharp reappraisal.
- The recent partnership with Samsung Bioepis to commercialize two FDA approved immunology biosimilars in the U.S. may support expectations for longer term revenue and cash flow contributions as those products roll into Teva's portfolio over time.
- If you'd rather focus on earnings, this one's for you. See why Teva Pharmaceutical Industries's 99.7x P/E tells a different valuation story.
The issue now is whether Teva Pharmaceutical Industries' current valuation is adequately explained by an intrinsic value estimate built from its cash flows.
If you want more ideas built around cash flow support rather than just share price excitement, a focused starting point is a list of 32 high quality undervalued stocks.
Does Teva Pharmaceutical Industries Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here takes Teva Pharmaceutical Industries' expected future free cash flows and brings them back to today's dollars. On the latest twelve month view, the group produced about $1.26b of free cash flow, and the model assumes that this figure grows from that base rather than shrinking, with projected free cash flow climbing into the low to mid single digit billions over the coming decade.
Those rising cash flow estimates, when discounted back and compared with the current share price of $43.24, lead to a DCF result that sits substantially above where the stock trades today. The recently announced U.S. biosimilars deal with Samsung Bioepis, which adds more products to Teva Pharmaceutical Industries' future portfolio, is one factor cited to explain why a cash flow based model can support a higher intrinsic worth than the market is currently assigning. Find out what Teva Pharmaceutical Industries could be worth using our Discounted Cash Flow (DCF) estimate.
The Teva Pharmaceutical Industries Narrative: What Would Justify Today's Price?
Narratives for Teva Pharmaceutical Industries act as the missing link between that cash flow based valuation puzzle and what actually needs to happen in the future for the current share price to make sense. They spell out the growth, margin and earnings paths that would need to hold for the stock to be worth materially more or less than today. Where a single ratio or model gives one number, these break that number into a storyline you can monitor over time on Simply Wall St's Community page.
One of the top narratives on Teva Pharmaceutical Industries: 12% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"A multiyear launch queue that targets one new asset submission or approval each year through at least 2030, including olanzapine LAI, ecopipam, DARI, emrusolmin and duvakitug…"
Discover why this Narrative puts Teva Pharmaceutical Industries at 12% undervalued.
Teva Pharmaceutical Industries is more than just a price tag
Share price and cash flow only tell part of the story for Teva Pharmaceutical Industries, because internal checks have also highlighted potential concerns that deserve your attention before you commit fresh capital. Take a closer look at 4 warning signs (1 major) before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com